BMRN
BioMarin Pharmaceutical Inc.
BMRN has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over BMRN overall, supported by stronger fundamentals and stronger modeled upside.
BMRN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Stable | |
| Weak |
BMRN's revenue is currently strong, and its cash flow is stable, but its profitability and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BMRN PE Valuation
BMRN has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BMRN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for BMRN, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
BMRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.46 | — |
| Q3 2026 | -$0.08 | -103% |
| Q2 2026 | $0.39 | -88% |
| Q1 2026 | $1.39 | -49% |
| Q4 2025 | $1.80 | -19% |
| Q3 2025 | $2.67 | +61% |
| Q2 2025 | $3.38 | +156% |
| Q1 2025 | $2.70 | +155% |
| Q4 2024 | $2.21 | +154% |
BMRN has swung to a loss: it lost $0.08 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BMRN on earnings quality, reporting a profit while its opponent remains loss making.
BMRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +32% |
| Q2 2026 | $989.7M | +20% |
| Q1 2026 | $766.2M | +2.8% |
| Q4 2025 | $874.6M | +17% |
| Q3 2025 | $776.1M | +4.1% |
| Q2 2025 | $825.4M | +16% |
| Q1 2025 | $745.1M | +15% |
| Q4 2024 | $747.3M | +16% |
BMRN's revenue has grown year over year for 19 quarters in a row: $1B last quarter, up 32% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -8% | -2 points |
| Q2 2026 | 11% | -22 points |
| Q1 2026 | 17% | -13 points |
| Q4 2025 | -5.1% | -27 points |
| Q3 2025 | -6% | -21 points |
| Q2 2025 | 34% | +17 points |
| Q1 2025 | 30% | +16 points |
| Q4 2024 | 22% | +19 points |
BMRN's operating margin was −8% last quarter, down 2 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BMRN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over BMRN on profitability, with a higher operating margin.
BMRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $159.9M | -53% |
| Q2 2026 | $139.3M | -17% |
| Q1 2026 | $199.7M | +27% |
| Q4 2025 | $58.9M | -65% |
| Q3 2025 | $340.2M | +68% |
| Q2 2025 | $168.2M | +73% |
| Q1 2025 | $157.6M | +655% |
| Q4 2024 | $166.1M | +$167.5M |
BMRN still generates free cash flow, though less than at its 2025 peak: $558M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BMRN on cash flow, with more consistent year-over-year improvement.
BMRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -877K shares |
| 1 year | +0.8% | +1.6M shares |
| 3 years | +1.3% | +2.4M shares |
| 5 years | +5.7% | +10.4M shares |
| Available history | +8.1% | +14.6M shares |
BMRN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BMRN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 9.1x | High |
| Q2 2026 | 11.0x | High |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -2.7x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.4x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.6x | Net Cash |
BMRN's net debt is about 9.1 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over BMRN on leverage, with a lower net debt burden relative to earnings.
BMRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.3 | Neutral |
| Stochastic | 24.3 | Neutral |
BMRN's weekly RSI is 45 (neutral) and its Stochastic is 24 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BMRN PE vs Healthcare Sector
| Metric | BMRN | Sector median | Relative |
|---|---|---|---|
| PE | 150x | 26x | 480% above |
| PE % | 67 | 29 | 38 pts above |
BMRN has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over BMRN on valuation relative to its sector.
BMRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $56.8 | 0.1% below |
| 20 week MA | $60.5 | 6.3% below |
| 50 week MA | $58.2 | 2.6% below |
| 100 week MA | $59.0 | 3.9% below |
| 200 week MA | $73.1 | 22% below |
BMRN is in a downtrend: it's below all five of its weekly moving averages, and 22% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BMRN on trend strength, trading above more of its moving averages.
BMRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $85.6 | $88.7 | +3.6% |
| 2021 | $88.7 | $91.2 | +2.8% |
| 2022 | $91.2 | $104.3 | +14% |
| 2023 | $104.3 | $96.4 | -7.6% |
| 2024 | $96.4 | $66.9 | -31% |
| 2025 | $66.9 | $60.0 | -10% |
| 2026 YTD | $60.0 | $56.7 | -5.4% |
BMRN has finished three years in a row lower, and it's down 5.4% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BMRN on returns for 2026, with the stronger performance.